A
Aaron L. Hecht
Researcher at University of Chicago
Publications - 8
Citations - 250
Aaron L. Hecht is an academic researcher from University of Chicago. The author has contributed to research in topics: Bacteroides fragilis & Bacteroides. The author has an hindex of 4, co-authored 6 publications receiving 193 citations.
Papers
More filters
Journal ArticleDOI
Strain competition restricts colonization of an enteric pathogen and prevents colitis
Aaron L. Hecht,Benjamin W. Casterline,Zachary M. Earley,Young Ah Goo,David R. Goodlett,Juliane Bubeck Wardenburg +5 more
TL;DR: A novel role of type VI secretion systems in colonization resistance against a pathogen is demonstrated and this understanding of bacterial competition may be utilized to define a molecularly targeted probiotic strategy.
Journal ArticleDOI
Activation of Bacteroides fragilis toxin by a novel bacterial protease contributes to anaerobic sepsis in mice
Vivian M. Choi,Julien Herrou,Aaron L. Hecht,Wei Ping Teoh,Jerrold R. Turner,Sean Crosson,Juliane Bubeck Wardenburg,Juliane Bubeck Wardenburg +7 more
TL;DR: A role is defined for B. fragilis enterotoxin and its activating protease in the pathogenesis of bloodstream infection, which indicates a greater complexity of cellular targeting and activity of BFT than previously recognized.
Journal ArticleDOI
The Bacteroides fragilis pathogenicity island links virulence and strain competition.
TL;DR: It is shown here that a second enterotoxigenic strain is competent to colonize, dependent on the Bacteroides fragilis pathogenicity island (BFPAI), suggesting that virulence factors may be adapted to modify the colonic niche to provide a strain-specific colonization advantage.
Journal ArticleDOI
A Two-Component System Regulates Bacteroides fragilis Toxin to Maintain Intestinal Homeostasis and Prevent Lethal Disease
TL;DR: It is found that Muc2-deficient mice succumb to lethal disease from ETBF colonization in a B. fragilis toxin (BFT)-dependent manner, and a toxin regulator, the two-component system RprXY, is identified, which suppresses BFT expression in vitro and in–vivo.